ALBO News and Press, Albireo Pharma Inc. From 04/26/21

Albireo developed Odevixibat- a product as a pipeline - as a life saving therapy for multiple ultra rare pediatric liver disease indications. The market potential is in the billions and well reachable with the announced positive Phase 3 results and PDUFA date set on 21 July. Launc...

Albireo Pharma (ALBO) announces the appointment of Joan Connolly as the company's Chief Technology Officer.In the new role, Connolly will be responsible for overseeing drug substance and product development, clinical supply distribution, commercial supply chain and quality. Mos...

– Appointment strengthens leadership team as the Company readies for potential global odevixibat launch and progresses multiple clinical development programs – – Deep experience spanning drug development, manufacturing, quality and supply chain – ...

BOSTON, April 06, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced participation in the upcoming Needham 20th Annual Healthcare Conference on April 12-15. Albireo executives takin...

– Dosed first patients in Phase 1 study with new product candidate A3907 – – First patient dosed in ASSERT global Phase 3 study of odevixibat for Alagille syndrome – – EMA & FDA reviewing odevixibat for PFIC, currently no plans for ...

– Calls to unite global communities affected by rare diseases – – Albireo supports increasing education and advances in research for rare cholestatic liver diseases – BOSTON, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: A...

Image source: The Motley Fool. Albireo Pharma, Inc. (NASDAQ: ALBO) Q4 2020 Earnings Call Feb 25, 2021 , 10:00 a.m. ET Operator Continue reading For further details see: Albireo Pharma, Inc. (ALBO) Q4 2020 Earnings Call Transcript

Albireo Pharma, Inc. (ALBO) Q4 2020 Earnings Conference Call February 25, 2021 10:00 AM ET Company Participants Paul Arndt - Managing Director-LifeSci Advisors Ron Cooper - President & Chief Executive Officer Simon Harford - Chief Financial Officer Pat Horn - Chief Medical Officer Pamela ...

The following slide deck was published by Albireo Pharma, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Albireo Pharma, Inc. 2020 Q4 - Results - Earnings Call Presentation

Albireo Pharma (ALBO): Q4 GAAP EPS of -$1.30 beats by $0.59.Revenue of $2.72M (-57.7% Y/Y) beats by $0.38M.Press Release For further details see: Albireo Pharma EPS beats by $0.59, beats on revenue